AtheroGenics, Inc.

AtheroGenics, Inc.

April 06, 2006 16:03 ET

AtheroGenics Schedules First Quarter Results Conference Call for April 20, 2006

ATLANTA, GA--(CCNMatthews - April 06, 2006) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it expects to release its first quarter 2006 results of operations on Thursday, April 20, 2006, before the U.S. financial markets open.

Company officials will provide a company update and discuss first quarter results via conference call and webcast on Thursday, April 20, 2006, at 9:00 a.m. ET. The conference call may be accessed by dialing 1-877-407-8031 (domestic) or 1-201-689-8031 (international), five minutes prior to the start time. A replay of the call will be available from 11:00 a.m. ET on Thursday, April 20, 2006, until 11:59 p.m. ET on April 27, 2006. Rebroadcast numbers are 1-877-660-6853 (domestic) or 1-201-612-7415 (international), account number 286 and conference ID number 198850. To access the webcast, log on to the Company's Investor Relations Web site and click on the Webcast Access link. An archived version of this webcast will be available at the same location through July 21, 2006.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectantr technology. For more information about AtheroGenics, please visit

Contact Information